Opportunity Information: Apply for RFA AI 24 074
The Combating Antibiotic-Resistant Bacteria Interdisciplinary Research Units (CARBIRUs) funding opportunity (RFA AI 24 074) is a National Institutes of Health (NIH) discretionary grant program that supports large, coordinated, multidisciplinary research efforts aimed at tackling antibiotic-resistant bacterial infections. The central goal is to fund integrated research programs that move from discovery through early development, generating the foundational knowledge, tools, and preclinical evidence needed to enable new ways to prevent infections, improve diagnosis, and develop better treatments. The activity is organized under a P01 mechanism (program project), which typically means multiple interrelated research projects are bundled into a single, collaborative program with shared scientific themes and strong coordination across teams. Clinical trials are not allowed under this announcement, so proposed work should focus on non-clinical-trial research such as basic, translational, and preclinical development activities.
This NOFO is positioned to encourage interdisciplinary “unit” style programs where microbiology, immunology, chemistry, pharmacology, diagnostics, bioengineering, computational biology, epidemiology (non-trial), and other relevant areas can be brought together to address antimicrobial resistance in a cohesive way. In practical terms, a competitive application would usually demonstrate how several projects and cores (as appropriate for a P01) fit together around a unifying strategy, for example: discovering novel bacterial targets or resistance mechanisms, developing or optimizing therapeutic candidates in early development stages, creating or validating diagnostic approaches (again, not clinical trial testing), and building platforms or resources that accelerate antibiotic discovery and evaluation. Because the scope emphasizes “discovery to early development,” the program is geared toward generating strong proof-of-concept and translational readiness rather than late-stage clinical validation.
The opportunity falls under the health funding activity category and is associated with CFDA number 93.855. The original closing date listed is 2025-03-26. The award ceiling is stated as $1,500,000, indicating the maximum award amount anticipated per award (as provided in the source data). While the expected number of awards is not specified in the provided listing, applicants should assume a competitive process where programmatic relevance, scientific merit, feasibility, and the added value of an integrated, interdisciplinary structure are key differentiators.
Eligibility is broad and includes many types of domestic U.S. organizations as well as certain non-U.S. entities. Eligible applicants include state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities/Indian housing authorities; Native American tribal organizations other than federally recognized governments; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; and small businesses. The announcement also explicitly calls out additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible agencies of the federal government, regional organizations, U.S. territories or possessions, Indian/Native American tribal governments other than federally recognized, and non-domestic (non-U.S.) entities/foreign organizations. This wide eligibility reflects NIH’s interest in drawing expertise from many sectors, including academia, government, community-based settings, and industry-aligned organizations, provided the proposed work aligns with the non-clinical-trial, early-stage research emphasis.
Overall, CARBIRUs is designed for teams that can show a clear, unified plan to produce actionable advances against antibiotic-resistant bacteria through coordinated projects that reinforce each other scientifically. The ideal program is one where the whole is stronger than the sum of its parts, with collaboration and shared direction enabling faster and more credible progress toward new prevention approaches, diagnostic capabilities, and therapeutic strategies without conducting clinical trials under this award.Apply for RFA AI 24 074
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Combating Antibiotic-Resistant Bacteria Interdisciplinary Research Units (CARBIRUs) (P01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855.
- This funding opportunity was created on 2024-11-04.
- Applicants must submit their applications by 2025-03-26. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $1,500,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs) - CARBIRUs (RFA AI 24 074)
What is the CARBIRUs funding opportunity?
The Combating Antibiotic-Resistant Bacteria Interdisciplinary Research Units (CARBIRUs) funding opportunity (RFA AI 24 074) is a National Institutes of Health (NIH) discretionary grant program that supports large, coordinated, multidisciplinary research efforts focused on antibiotic-resistant bacterial infections.
What is the main goal of this program?
The central goal is to fund integrated research programs that move from discovery through early development, producing foundational knowledge, tools, and preclinical evidence that can enable new ways to prevent infections, improve diagnosis, and develop better treatments for antibiotic-resistant bacteria.
What grant mechanism is used for this opportunity?
This opportunity is organized under the P01 mechanism (program project). In general, a P01 supports multiple interrelated research projects bundled into a single, collaborative program with shared scientific themes and strong coordination across teams.
Are clinical trials allowed under this announcement?
No. Clinical trials are not allowed under this announcement. Proposed work should focus on non-clinical-trial research such as basic research, translational research, and preclinical development activities.
What types of research activities fit the "discovery to early development" focus?
Based on the description provided, aligned activities may include discovering novel bacterial targets or resistance mechanisms, developing or optimizing therapeutic candidates in early development stages, creating or validating diagnostic approaches (without clinical trial testing), and building platforms or resources that accelerate antibiotic discovery and evaluation.
What scientific disciplines are encouraged to be part of a CARBIRUs program?
The opportunity is positioned to encourage interdisciplinary, "unit" style programs that can integrate fields such as microbiology, immunology, chemistry, pharmacology, diagnostics, bioengineering, computational biology, and epidemiology (non-trial), along with other relevant areas that contribute to addressing antimicrobial resistance.
What does "interdisciplinary unit" mean in practical application terms?
In practical terms, the program encourages applicants to form a cohesive, coordinated team where multiple projects (and cores, as appropriate for a P01) are integrated around a unifying scientific strategy. The emphasis is on collaboration and shared direction so the overall program produces more impact than isolated projects would.
What outcomes is CARBIRUs trying to enable?
CARBIRUs is designed to generate actionable advances against antibiotic-resistant bacteria by supporting research that can lead toward new prevention approaches, improved diagnostics, and better therapeutic strategies, supported by strong proof-of-concept and translational readiness (without moving into clinical trials under this award).
Is late-stage clinical validation part of the intended scope?
No. The scope emphasizes discovery through early development and is geared toward generating strong proof-of-concept and translational readiness rather than late-stage clinical validation.
What is the funding activity category for this opportunity?
The opportunity falls under the health funding activity category.
What is the CFDA number associated with this opportunity?
The associated CFDA number is 93.855.
What is the original closing date listed for this opportunity?
The original closing date listed is 2025-03-26.
What is the award ceiling for this grant opportunity?
The award ceiling is stated as $1,500,000, indicating the maximum award amount anticipated per award (as provided in the source data).
How many awards will be made?
The expected number of awards is not specified in the provided listing.
What kinds of organizations are eligible to apply?
Eligibility is broad and includes many types of domestic U.S. organizations as well as certain non-U.S. entities. Eligible applicant types include: state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities/Indian housing authorities; Native American tribal organizations other than federally recognized governments; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; and small businesses.
Are minority-serving institutions specifically mentioned as eligible?
Yes. The announcement explicitly calls out Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs) among eligible applicant categories.
Are faith-based or community-based organizations eligible to apply?
Yes. Faith-based or community-based organizations are explicitly mentioned as eligible applicant categories.
Are federal agencies eligible to apply?
Yes. Eligible agencies of the federal government are included among the eligible applicant categories.
Are U.S. territories or possessions included in eligibility?
Yes. U.S. territories or possessions are explicitly mentioned as eligible applicant categories.
Are non-U.S. (foreign) organizations eligible to apply?
Yes. The announcement includes non-domestic (non-U.S.) entities/foreign organizations among eligible applicants.
What does the program suggest about competitiveness and review considerations?
Since the number of awards is not specified, applicants should assume a competitive process where programmatic relevance, scientific merit, feasibility, and the added value of an integrated, interdisciplinary structure are key differentiators.
What is the overall program design NIH appears to be seeking?
The program is designed for teams that can present a clear, unified plan where coordinated projects reinforce each other scientifically. The ideal program is described as one where the whole is stronger than the sum of its parts, accelerating credible progress toward solutions for antibiotic-resistant bacterial infections while remaining within the non-clinical-trial scope.
Browse more opportunities from the same category: Health
Next opportunity: FY25 IIJA/IRA Bureau of Land Management Idaho (ID) Forest and Woodlands Resource Management
Previous opportunity: Mechanistic links between diet, lipid metabolism, and tumor growth and progression (UH2 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 24 074
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 24 074) also looked into and applied for these:
| Funding Opportunity |
|---|
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional) Apply for PAR 25 036 Funding Number: PAR 25 036 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIA Multi-site Clinical Trial Implementation Grant (R01 Clinical Trial Required) Apply for PAR 25 222 Funding Number: PAR 25 222 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIA Academic Leadership Career Award (K07 Independent Clinical Trial Not Allowed) Apply for PAR 24 321 Funding Number: PAR 24 321 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed) Apply for PAR 25 063 Funding Number: PAR 25 063 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| USAID Thamini Afya (Value your Health) Apply for 72062125RFA00001 Funding Number: 72062125RFA00001 Agency: Tanzania USAID-Dar es Salaam Category: Health Funding Amount: $16,450,000 |
| Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed) Apply for PAR 25 198 Funding Number: PAR 25 198 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed) Apply for PAR 25 199 Funding Number: PAR 25 199 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Research Infrastructure Development for Interdisciplinary Aging Studies (R61/R33 - Clinical Trial Optional) Apply for PAR 25 218 Funding Number: PAR 25 218 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required) Apply for PAR 25 049 Funding Number: PAR 25 049 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33 Clinical Trial Optional) Apply for PAR 25 219 Funding Number: PAR 25 219 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed) Apply for PAR 25 234 Funding Number: PAR 25 234 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Laboratories to Optimize Digital Health (R01 Clinical Trial Required) Apply for PAR 25 136 Funding Number: PAR 25 136 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required) Apply for PAR 25 054 Funding Number: PAR 25 054 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional) Apply for PAR 25 133 Funding Number: PAR 25 133 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Not Allowed) Apply for PAR 25 027 Funding Number: PAR 25 027 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIMHD Minority Health and Health Disparities Research Training (MHRT) Program (T37 Clinical Trial Not Allowed) Apply for RFA MD 25 001 Funding Number: RFA MD 25 001 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Exploratory/Developmental Research on Guillain Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (R21 - Clinical Trial Not Allowed) Apply for RFA NS 25 025 Funding Number: RFA NS 25 025 Agency: National Institutes of Health Category: Health Funding Amount: $3,000,000 |
| Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed) Apply for PAR 25 202 Funding Number: PAR 25 202 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Focused Technology Research and Development (R01 Clinical Trial Not Allowed) Apply for PAR 25 203 Funding Number: PAR 25 203 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Global Health Security Activity Apply for 72052025RFA00002 Funding Number: 72052025RFA00002 Agency: Guatemala USAID-Guatemala City Category: Health Funding Amount: $40,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 24 074", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.